BMS-188667 (Bristol-Myers Squibb).
Bristol-Myers Squibb is developing CTLA4-Ig, an immunosuppressant immunoglobulin, for the potential treatment of various immunological disorders, including graft versus host disease, lupus erythematosus and psoriasis. A phase II trial has commenced for psoriasis. The compound is also in development for inflammation, rheumatoid arthritis and allergy. A collaboration with Genzyme Transgenics covers the following indications: psoriasis; organ transplant rejection; and several autoimmune disorders.
Dumont
F J
FJ
Department of Immunology, Merck Research Laboratories, Rahway, NJ 07065, USA. francis_dumont@merck.com